ArticleFrontiers in endocrinology2025
Characteristics of the gut microbiome of asymptomatic hyperuricemia.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Asymptomatic hyperuricemia(AH) is characterized by elevated blood uric acid levels without symptoms,posing risks like gout, kidney stones, and cardiovascular diseases. This study aims to investigate the role of the gut microbiota in uric acid metabolism in AH. Methods: Clinical data from 30 AH patients and 30 healthy controls were collected. Fecal microbiota genomic DNA was extracted, PCR amplified, library constructed, and sequenced. Bioinformatics and statistical analyses were conducted to study the gut microbiota of the two groups. Results: The AH group exhibited significantly elevated levels of body mass index (BMI), Triglycerides (TG), Total Cholesterol (TC), as along with a history of smoking, hypertension, and fatty liver disease compared to the healthy group (P < 0.05). The overall richness and ecological diversity of gut microbiota in the AH group decreased, with differences in the distribution at the phylum and genus levels compared to the healthy group. Uric acid demonstrated significant correlations with various gut microbiota (e.g., Granulicatella), suggesting their potential as biomarkers for AH. Despite limitations such as a small sample size and lack of long-term follow-up, our findings provide new insights for the early diagnosis and personalized treatment of AH. Looking ahead, these discoveries may advance the clinical management of AH and the exploration of associated biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.